TriangleRevumenib + 7+3 + Midostaurin (NCT06313437)
Revumenib + 7+3 + Midostaurin trial for Newly Diagnosed NPM1- and FLT3-Mutated AML (NCT06313437). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed acute myeloid leukemia with both NPM1 and FLT3 mutations.
The idea: add revumenib, a menin inhibitor pill, to standard induction chemotherapy, cytarabine and daunorubicin by vein, plus midostaurin, a pill that targets FLT3. Revumenib also continues with one cycle of therapy after remission.
The study looks for a safe and effective dose of revumenib.
This phase 1 study plans 22 patients. At Dana-Farber Cancer Institute in Boston, Richard Stone leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.